Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 3/20 | 0.53 |
| ▸ | KDR | P35968 | 7/20 | 0.51 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.49 |
| ▸ | RET | P07949 | 5/20 | 0.49 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.47 |
| ▸ | FLT3 | P36888 | 1/20 | 0.47 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.45 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.45 |
| ▸ | TLK2 | Q86UE8 | 2/20 | 0.45 |
| ▸ | AKT2 | P31751 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12336334 | 0.88 | ALK (0.72) | ALKKDRPDGFRBRETFGFR1 | |
| SCHEMBL15202695 | 0.81 | KDR (0.65) | ALKKDRPDGFRBRETFGFR1 | |
| SCHEMBL15203009 | 0.80 | KDR (0.61) | ALKKDRPDGFRBRETFGFR1 | |
| SCHEMBL12335933 | 0.80 | PRKAA1 (0.76) | ALKKDRPDGFRBRETFGFR1 | |
| SCHEMBL12335941 | 0.80 | MET (0.64) | ALKKDRPDGFRBRETFGFR1 | |
| SCHEMBL12335938 | 0.80 | KDR (0.75) | ALKKDRPDGFRBRETFGFR1 | |
| SCHEMBL12335796 | 0.79 | SRC (0.43) | ALKKDRPDGFRBRETFGFR1 | |
| SCHEMBL12335795 | 0.79 | PDGFRB (0.45) | ALKKDRPDGFRBRETFGFR1 | |
| SCHEMBL15202702 | 0.78 | AKT2 (0.66) | ALKKDRPDGFRBFGFR1PDPK1 | |
| SCHEMBL12335950 | 0.78 | KDR (0.77) | ALKKDRPDGFRBRETFGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9539239-B1 | Compositions and methods for treatment of neurodegenerative disease | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2017-01-10 | — | — | US | disclosed |
| US-9539239-B1 | Compositions and methods for treatment of neurodegenerative disease | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2017-01-10 | — | — | US | disclosed |
| US-20160367527-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF NEURODEGENERATIVE DISEASE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2016-12-22 | — | — | US | disclosed |
| US-20160367527-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF NEURODEGENERATIVE DISEASE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2016-12-22 | — | — | US | disclosed |
| US-20130217679-A1 | Compositions and Methods for Treatment of Neurodegenerative Disease | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-08-22 | — | — | US | disclosed |
| US-20130217679-A1 | Compositions and Methods for Treatment of Neurodegenerative Disease | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-08-22 | — | — | US | disclosed |
| WO-2011119777-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF NEURODEGENERATIVE DISEASE | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160367527-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF NEURODEGENERATIVE DISEASE | CLN6, PSEN2, CHAT | ALK 4816/4885KDR 4527/4885PDGFRB 3455/4885 |
| US-20130217679-A1 | Compositions and Methods for Treatment of Neurodegenerative Disease | CLN6, PSEN2, CHAT | ALK 4816/4885KDR 4527/4885PDGFRB 3455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.